Dosage Options

Dosage Options

Dosage forms & strengths

ELIGARD provides flexible dosing options with technology that enables small injection volumes. [1]

The injection delivers the dose of leuprolide acetate incorporated in a polymer formulation.

7.5 mg
(every month)		22.5 mg
(every 3-months)		30 mg
(every 4-months)		45 mg
(every 6-months)
Injection Volume0.25 mL0.375 mL0.50 mL0.375 mL
Table: Dosing and injection volumes

ELIGARD® is an injectable suspension of leuprolide acetate available in a single- dose kit. The kit consists of two prefilled syringes whose contents are mixed immediately prior to administration.

The syringes are packaged separately: Syringe A contains the in-situ polymeric gel extended Delivery System and the Syringe B contains leuprolide acetate powder. The two syringes are joined and the single dose product is mixed until it is homogenous. [1] When reconstituted, ELIGARD is administered as a single dose.

The kit also contains a sterile safety needle (Table 1), a desiccant, and a package insert for reconstitution and administration procedures.

ELIGARD strengthGaugeLength
7.5 mg (1 injection every month)20-gauge5/8-inch
22.5 mg (1 injection every 3-months)20-gauge5/8-inch
30 mg (1 injection every 4-months)20-gauge5/8-inch
45 mg (1 injection every 6-months)18-gauge5/8-inch
Table 1: Specifications for ELIGARD® Sterile Safety Needle

See Mixing & Administration for full details.

Use our Dosing Calculator tool to determine a patient’s next injection date.

References
  1. ELIGARD® (leuprolide acetate) for injectable suspension 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019.

IMPORTANT SAFETY INFORMATION

Expand Minimize

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. See package insert for full Prescribing and Safety Information.